These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21034259)

  • 1. Low concentrations of serum n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease patients with liver injury.
    Kishino T; Ohnishi H; Ohtsuka K; Matsushima S; Urata T; Watanebe K; Honda Y; Mine Y; Matsumoto M; Nishikawa K; Mori H; Takahashi S; Ishida H; Watanabe T
    Clin Chem Lab Med; 2011 Jan; 49(1):159-62. PubMed ID: 21034259
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.
    Sofi F; Giangrandi I; Cesari F; Corsani I; Abbate R; Gensini GF; Casini A
    Int J Food Sci Nutr; 2010 Dec; 61(8):792-802. PubMed ID: 20465434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum omega-3 polyunsaturated fatty acid and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease].
    Zhu QQ; Lou DJ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ; Li D
    Zhonghua Nei Ke Za Zhi; 2010 Apr; 49(4):305-8. PubMed ID: 20627036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease.
    Spadaro L; Magliocco O; Spampinato D; Piro S; Oliveri C; Alagona C; Papa G; Rabuazzo AM; Purrello F
    Dig Liver Dis; 2008 Mar; 40(3):194-9. PubMed ID: 18054848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study.
    Parker HM; O'Connor HT; Keating SE; Cohn JS; Garg ML; Caterson ID; George J; Johnson NA
    Br J Nutr; 2015 Sep; 114(5):780-7. PubMed ID: 26202539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A biochemical view: Increase in polyunsaturated fatty acid ω-6/ω-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease.
    Sertoglu E; Kayadibi H; Uyanik M
    J Diabetes Complications; 2015; 29(1):157. PubMed ID: 25455415
    [No Abstract]   [Full Text] [Related]  

  • 8. [Research on the relationship between non-alcoholic fatty liver disease and platelet phospholipid fatty acids].
    Yu XM; Li D; Xie HB; Wang Q; Xu AM; Bi QH; Ye XW; Fan FH
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):225-6. PubMed ID: 19335990
    [No Abstract]   [Full Text] [Related]  

  • 9. Endogenously synthesized n-3 polyunsaturated fatty acids in fat-1 mice ameliorate high-fat diet-induced non-alcoholic fatty liver disease.
    Kim EH; Bae JS; Hahm KB; Cha JY
    Biochem Pharmacol; 2012 Nov; 84(10):1359-65. PubMed ID: 22981383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes.
    Petit JM; Guiu B; Duvillard L; Jooste V; Brindisi MC; Athias A; Bouillet B; Habchi M; Cottet V; Gambert P; Hillon P; Cercueil JP; Verges B
    Clin Nutr; 2012 Aug; 31(4):520-5. PubMed ID: 22209679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.
    Arendt BM; Comelli EM; Ma DW; Lou W; Teterina A; Kim T; Fung SK; Wong DK; McGilvray I; Fischer SE; Allard JP
    Hepatology; 2015 May; 61(5):1565-78. PubMed ID: 25581263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis.
    Basili S; Raparelli V; Napoleone L; Del Ben M; Merli M; Riggio O; Nocella C; Carnevale R; Pignatelli P; Violi F;
    Dig Liver Dis; 2014 Jul; 46(7):632-8. PubMed ID: 24703705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease.
    Elizondo A; Araya J; Rodrigo R; Signorini C; Sgherri C; Comporti M; Poniachik J; Videla LA
    Biol Res; 2008; 41(1):59-68. PubMed ID: 18769764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease.
    Monteiro J; Leslie M; Moghadasian MH; Arendt BM; Allard JP; Ma DW
    Food Funct; 2014 Mar; 5(3):426-35. PubMed ID: 24496399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of adipokines by polyunsaturated fatty acids in a rat model of non-alcoholic steatohepatitis.
    Ding WJ; Wang Y; Fan JG
    Arch Iran Med; 2014 Aug; 17(8):563-8. PubMed ID: 25065280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis.
    López-Vicario C; González-Périz A; Rius B; Morán-Salvador E; García-Alonso V; Lozano JJ; Bataller R; Cofán M; Kang JX; Arroyo V; Clària J; Titos E
    Gut; 2014 Feb; 63(2):344-55. PubMed ID: 23492103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of diet and omega-3 fatty acids in NAFLD.
    Popescu LA; Vîrgolici B; Lixandru D; Miricescu D; Condruţ E; Timnea O; Ranetti AE; Militaru M; Mohora M; Zăgrean L
    Rom J Morphol Embryol; 2013; 54(3 Suppl):785-90. PubMed ID: 24322028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease.
    Masterton GS; Plevris JN; Hayes PC
    Aliment Pharmacol Ther; 2010 Apr; 31(7):679-92. PubMed ID: 20415840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
    Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
    Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omega 3 - Omega 6: What is right for the liver?
    El-Badry AM; Graf R; Clavien PA
    J Hepatol; 2007 Nov; 47(5):718-25. PubMed ID: 17869370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.